Lexaria Bioscience Corp Net Income per Employee (LEXX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Lexaria Bioscience Corp   (NASDAQ: LEXX)
 

Lexaria Bioscience Net Income per Employee

LEXX's Quarterly Results, Trends, Rankings, Statistics
Lexaria Bioscience Corp recorded a cumulative net loss of $-8 million during 12 month ending in the third quarter 2026.
The Healthcare sector has seen employees of 271 other companies achieving higher income per employee. While Lexaria Bioscience 's total ranking has deteriorated compared to the previous quarter from 936 to 3800.


What is Income per Employee Ratio?






LEXX Net Income per Employee (May 31 2026)
III. Quarter
(Feb 28 2026)
II. Quarter
(Nov 30 2025)
I. Quarter
(Aug 31 2025)
IV. Quarter
(May 31 2025)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,105,778 -1,362,581 -1,543,187 -1,701,633 -1,628,682
LEXX's Total Ranking # 3800 # 936 # 3374 # 2899 # 3027
Seq. Net Income Change - - - - -


LEXX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 272
Healthcare Sector # 673
Overall Market # 3800

Net Income per Employee Statistics
High Average Low
$ -164,614 $ -770,505 $ -1,701,633
(Aug 31 2016)   (Aug 31 2025)







Companies with similar Income per Employee for 12 month ending May 31 2026, within Healthcare Sector Income per Employee Income 12 month ending May 31 2026Number of Employees May 31 2026


Date modified: 2026-08-03T18:30:59+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.